Owing to the aberrant expression of PFKFB3 and PKM2 in cancer cells compared with their corresponding “normal” cell counterparts, targeting these glycolytic enzymes might provide a means to target Ca2+ pumps specifically in cancer cells. This evidence concerns the gene PKM and cancer.